Beata Mala
Cardiovascular Disease · New York, NYNPI 1376158196
Payments from drug & device makers
Across 167 payments — averaging $31.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Amgen$1K
- Novartis$833
- Pfizer$379
- AstraZeneca$339
- Lilly USA, LLC$253
- plus $692 from 8 others
What the payments were for
- Food & beverage$5,207100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $1,421 |
| Amgen | 48 | $1,290 |
| Novartis | 25 | $833 |
| Pfizer | 15 | $379 |
| AstraZeneca | 11 | $339 |
| Lilly USA, LLC | 4 | $253 |
| Irhythm Technologies, Inc. | 2 | $167 |
| Philips North America LLC | 4 | $131 |
| Johnson & Johnson | 5 | $120 |
| Boehringer Ingelheim | 4 | $117 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| Alnylam Pharmaceuticals Inc. | 1 | $31 |
| Esperion Therapeutics, Inc. | 1 | $29 |
| Kestra Medical Technology Services, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,207 in reported general payments places this provider in the 70th percentile of 2,302 cardiovascular disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone | 11 | $1,488 |
| Atorvastatin Calcium | 27 | $186 |
| Rosuvastatin Calcium | 13 | $122 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Anuradha Lala-TrindadeNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.